一種新型軟件模塊為放射科醫(yī)生提供了一種血管分析系統(tǒng)，能夠有效評估對比增強(qiáng)計(jì)算機(jī)X線斷層血管成像術(shù)和核磁共振檢查評估血管狹窄、支架和支架放置計(jì)劃、以及支架放置監(jiān)測。

這種三維VesselMetrix模塊是由Barco公司開發(fā)的，最近剛剛獲得美國食品藥品管理局的許可。Voxar產(chǎn)品小組總經(jīng)理Craig Anderson指出："VesselMetirx得到了我們客戶和PACS(圖像存檔和通信系統(tǒng))合作伙伴的認(rèn)可，因?yàn)樗子诓僮鳎ぷ鞣€(wěn)定可靠。它使得放射科醫(yī)生在閱讀血管成像資料的時(shí)候，對質(zhì)量和效率制定新的標(biāo)準(zhǔn)。"

他說："我們的客戶和PACS合作伙伴需要三維臨床應(yīng)用軟件，要求用戶界面友好并能夠提高工作效率。VeslMetrix滿足了血管成像研究的要求，達(dá)到了我們?yōu)榉派淇漆t(yī)生提供他們所需要的能夠有效閱讀龐大的測定容量數(shù)據(jù)研究的基本要求。"
 
Software for 3D Vessel Analysis
 
A new software module provides radiologists with a vessel analysis system to effectively assess contrast-enhanced computed tomography angiography (CTA) and magnetic resonance angiography (MRA) studies for evaluating stenosis, stent and stent graft planning, and stent graft monitoring.

The 3D (three-dimensional) VesselMetrix module, developed by Barco (Kortrijk, Belgium), has just been cleared by the U.S. Food and Drug Administration (FDA). “VesselMetrix was very well received by our customers and PACS [picture archiving and communications system] partners because of its ease-of-use and incredibly fast performance. It allows radiologists to set new standards in quality and efficiency when reading angiographic studies,” stated Craig Anderson, general manager of the Voxar product group.

“Our customers and PACS partners need 3D-enabled clinical software applications that are user-friendly and optimized to increase productivity. VeselMetrix delivers this for angiographic studies and is fundamental to our goal of providing radiologists with the tools they need to effectively read large volumetric data studies,” he added.